Q
28.36
0.23 (0.82%)
| Previous Close | 28.13 |
| Open | 27.08 |
| Volume | 2,196,764 |
| Avg. Volume (3M) | 943,123 |
| Market Cap | 1,912,782,720 |
| Price / Earnings (Forward) | 10.10 |
| Price / Sales | 0.610 |
| Price / Book | 0.570 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 11 May 2025 |
| Profit Margin | -73.74% |
| Operating Margin (TTM) | 6.64% |
| Diluted EPS (TTM) | -30.54 |
| Quarterly Revenue Growth (YOY) | -4.70% |
| Total Debt/Equity (MRQ) | 89.84% |
| Current Ratio (MRQ) | 1.22 |
| Operating Cash Flow (TTM) | 83.00 M |
| Levered Free Cash Flow (TTM) | 211.81 M |
| Return on Assets (TTM) | 0.65% |
| Return on Equity (TTM) | -51.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | QuidelOrtho Corporation | Bearish | Bearish |
AIStockmoo Score
1.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 0.0 |
| Average | 1.13 |
|
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 0.78% |
| % Held by Institutions | 109.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 61.00 (RBC Capital, 115.09%) | Buy |
| Median | 45.00 (58.67%) | |
| Low | 25.00 (JP Morgan, -11.85%) | Sell |
| Average | 43.67 (53.98%) | |
| Total | 1 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 36.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 21 Apr 2025 | 25.00 (-11.85%) | Sell | 25.17 |
| RBC Capital | 13 Feb 2025 | 61.00 (115.09%) | Buy | 41.65 |
| UBS | 13 Feb 2025 | 45.00 (58.67%) | Hold | 41.65 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Apr 2025 | Announcement | QuidelOrtho to Report First Quarter 2025 Financial Results |
| 10 Mar 2025 | Announcement | QuidelOrtho® Introduces Results Manager™ System |
| 24 Feb 2025 | Announcement | QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference |
| 12 Feb 2025 | Announcement | QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |